Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

JAMA Network

This nonrandomized phase 2 trial examines remission after combination therapy with ibrutinib and venetoclax in treatment-naive patients with chronic lymphocytic leukemia.

  • Phase II single arm data of frontline Ibrutinib and venetoclax in older or high risk patients with CLL. Patients had either del(17p), TP53-mutated, del(11q), unmutated IgVH, or age 65 years or older. 75% of patients achieved marrow uMRD as best response. Estimated 3 year PFS was 93%.